NDAOPHTHALMICOINTMENT
Approved
Jan 1950
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AUREOMYCIN (chlortetracycline hydrochloride) is a tetracycline antibiotic ointment approved in 1950 for ophthalmic use. It is indicated for bacterial eye infections and works by inhibiting bacterial protein synthesis. The drug represents an era of broad-spectrum antibiotic therapy now largely superseded by newer agents.
LOE Approaching
This legacy product is approaching loss of exclusivity with modest competitive pressure (30% index), indicating limited team expansion and focus on managed decline.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on AUREOMYCIN offers limited career growth potential due to the product's mature lifecycle and LOE trajectory. This role is suitable for professionals focused on lifecycle management, operational efficiency, and stewardship of legacy assets rather than launch or expansion experience.
Brand ManagerCommercial Operations
Worked on AUREOMYCIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.